Defining response to anti-VEGF therapies in neovascular AMD

Amoaku, W M, Chakravarthy, U, Gale, R, Gavin, M, Ghanchi, F, Gibson, J, Harding, S, Johnston, R L +8 more·2015·Eye
DOI 10.1038/eye.2015.48

Cited by (349)

Items 301–349 of 349

  1. Hypothetical Switch of Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis
    Cengiz Türksever, Gábor Márk Somfai, Susanne Oesch, Tobias Machewitz, Pascal Willy Hasler, Sandrine Anne Zweifel · 2022 · Ophthalmology and Therapy
  2. Comment on “One-year outcomes of the treat-and-extend approach with aflibercept in age-related macular degeneration: Effects on typical choroidal neovascularization and retinal angiomatous proliferation”
    Konstantinos T. Tsaousis, G DE LA MATA, Sreekala Burgula · 2018 · Archivos de la Sociedad Española de Oftalmología (English Edition)
  3. Nuevas Opciones de Anti-VEGF Aprobados por la FDA para el Manejo de la Degeneración Macular Húmeda Asociada a la Edad
    Carolina Sardi, Javier Antonio Buendía-Berdugo, Dra. Claudia Acosta-Cadavid, Juan Gonzalo Sánchez-Montoya · 2022 · Highlights of Vitreoretina
  4. Age-related Macular Degeneration patient deep phenotyping and whole genome sequencing analysis identifies coding variants linking small low-luminance visual deficit to fat storage defects
    Sehyun Kim, Amy Stockwell, Han Qin, Simon S. Gao, Meredith S. Sagolla, Ivaylo Stoilov, Arthur Wüster, Phillip Lai, Brian L. Yaspan, Marion Jeanne · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  5. Clinical Phenotypes of Patients with Neovascular Age-Related Macular Degeneration and Poor Response to Aflibercept Treatment
    В. Г. Лихванцева, A. S. Gevorgyan, S. G. Kapkova, E. Yu. Nekrasova · 2022 · Ophthalmology in Russia
  6. Differential Effects of Resveratrol on HECa10 and ARPE-19 Cells
    Monika Leśniak, Dariusz Rokicki, Agnieszka Synowiec, Aleksandra Filipiak-Duliban, Piotr Skopiński, Aneta Lewicka, Sławomir Lewicki · 2022 · Applied Sciences
  7. A model-based approach for historical borrowing, with an application to neovascular age-related macular degeneration
    Francesco Brizzi, Bernhard Steiert, Herbert Pang, Cheikh Diack, Mark Lomax, Robbie Peck, Zoe Morgan, Antoine Soubret · 2023 · Statistical Methods in Medical Research
  8. Retinal pigment epithelium elevation values as a marker in determining the anatomical prognosis and treatment regimen of type 2 macular neovascularization
    Mehmed Uğur Işık, Zübeyir Yozgat · 2023 · Research Square
  9. Assessment of efficiency of change of inhibitor of angiogenesis at a takhifilaksiya of a neovascular age makulyarny degeneration to systematic antiangiogenic therapy
    Alexei N. Kulikov, S. V. Sosnovsky, N. A. Gribanov, Березин Роман Дмитриевич, D.H. Oskanov, K. S. Ivanova · 2017 · Bulletin of the Russian Military Medical Academy
  10. The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration
    Laura García‐Quintanilla, Pablo Almuiña-Varela, María José Rodríguez‐Cid et al. · 2024 · Pharmaceutics
  11. Dielectrophoretic characterization of peroxidized retinal pigment epithelial cells as a model of age-related macular degeneration
    Dharm Singh Yadav, Ioan Cristian Tivig, Tudor Savopol, Mihaela Georgeta Moisescu · 2024 · BMC Ophthalmology
  12. Comparing macular thickness and visual acuity responses retinal vein occlusion versus diabetic macular edema following anti vascular endothelial growth factor therapy: A retrospective analysis
    Achyut Pandey, Rangkynsai Marngar, Shweta Sharma · 2024 · Indian Journal of Clinical and Experimental Ophthalmology
  13. Aqueous humor mediator levels as biomarkers of anti-VEGF response in age-related macular degeneration
    Stéphanie Baillif, Sacha Nahon‐Estève, Tanguy Pacé-Loscos, Gilles Pagès, Maeva Dufies · 2025 · Cytokine
  14. A Synthetic Nonapeptide Inhibits Angiogenesis and Vascular Permeability Via Vegfr-2 Antagonism, and its Ocular Instillation Attenuates Macular Neovascularization in Age-Related Macular Degeneration Animal Models
    Eung-Ji Lee, Ha-Na Gil, Yong Ji Chung, Eun Mi Kim · 2025 · SSRN Electronic Journal
  15. Association of neutrophil-to-lymphocyte ratio and neutrophil activation with treatment response in neovascular AMD
    Alexander Kai Thomsen, Maria Abildgaard Steffensen, Kathrine Gotfredsen, Henrik Vorum, Bent Honoré, Mogens Holst Nissen, Torben Lykke Sørensen · 2025 · AJO International
  16. Connecting the dots: investigating the correlation between anatomic and visual outcomes in neovascular age-related macular degeneration and retinal vascular diseases
    Karl G. Csaky, Sophie J. Bakri, Justis P. Ehlers, Avni P. Finn, Michael S. Ip · 2025 · Expert Review of Ophthalmology
  17. Clinical Features and Optical Coherence Tomography Angiography in Neovascular Age-Related Macular Degeneration and Pachychoroid Neovasculopathy
    Angsita Khaohoen, Yodpong Chantarasorn · 2025 · Journal of VitreoRetinal Diseases
  18. CircRNA MALAT1/miR-96-5p/FOXK2 axis regulates choroidal neovascularization
    Yue Yin, Tong Zhao · 2025 · Clinics
  19. Elevated ApoB/A1 ratio predicts enhanced short-term efficacy of anti-VEGF therapy in diabetic macular edema
    Weiyi Zhang, Yuling Zou · 2025 · Scientific Reports
  20. Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment
    Arshad M. Khanani, Sophie J. Bakri, Carl D. Regillo, Christina Y. Weng, Tien Yin Wong, Megan E. Baldwin, John J. Han, Ian M. Leitch · 2025 · Eye
  21. Polycation-based miRNA delivery system for choroidal neovascularization treatment
    Qiannan Cao, Liang Yu, Weiyi Xia, Anna Guo, Mingxia Jiang, Lai Yang, Qiaoyan Dong, Wenming Zheng, Yufei Yao, Siting Zhang et al. · 2025 · Chinese Chemical Letters
  22. Cessation of Anti‐ VEGF Treatment Therapy in Age‐Related Macular Degeneration: A Narrative Review
    Eiman Usmani, Bobak Bahrami, Andreas Ebneter, Weng Onn Chan · 2025 · Clinical and Experimental Ophthalmology
  23. Approved antiangiogenic and proangiogenic drugs in the past two decades: a historical landscape of the therapeutic opportunities
    Guido Bocci · 2025 · Elsevier eBooks
  24. Predictors of response to bevacizumab monotherapy in polypoidal choroidal vasculopathy: a 12-month retrospective study
    Chinnapat Montrisuksirikun, Supredee Pongrujikorn, Nuttawut Rodanant, Somanus Thoongsuwan, Supalert Prakhunhungsit, Nida Wongchaisuwat, Nopasak Phasukkijwatana · 2026 · International Journal of Retina and Vitreous
  25. CD8+ T cell aging is associated with macular neovascularization area change in neovascular age-related macular degeneration: a prospective cohort study
    Alexander Kai Thomsen, Maria Abildgaard Steffensen, Kathrine Gotfredsen, Henrik Vorum, Bent Honoré, Mogens Holst Nissen, Torben Lykke Sørensen · 2026 · BMC Ophthalmology
  26. Fluorescence lifetime imaging ophthalmoscopy (FLIO) of patients with neovascular age-related macular degeneration before and after treatment with intravitreal ranibizumab
    Svenja Rebecca Sonntag, Stella Fries, Stefanie Gniesmer, Salvatore Grisanti, Yoko Miura · 2026 · Graefe s Archive for Clinical and Experimental Ophthalmology
  27. Intravitreal Brolucizumab Use for Retinal Vascular Diseases in Resource-Constrained Settings: A Retrospective Study From Bangladesh
    Muhammad Moniruzzaman, Mohammed Azzam, Mst. Sayedatun Nessa · 2026 · Cureus
  28. Single Cell Transcriptomics and Surface Protein Expression Reveal Distinct Cellular and Molecular Phenotypes in Human RPESC-RPE and PSC-RPE
    Swapna Nandakumar, Farhad Farjood, Taylor B. Bertucci, Steven Lotz, Skanda Sai, Yue Wang, Jade A. Kozak, Brigitte L. Arduini, Jeffrey H. Stern, Nathan C. Boles et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  29. OCT-based morphological prognostic factors for structural improvement after anti-VEGF therapy in wet age-related macular degeneration
    Tengbo Rao, Jiarui Yang, Huijin Chen, Xuemin Li · 2026 · BMC Ophthalmology
  30. Bevacizumab-polymer conjugate for enhanced stability and anti-angiogenic activity
    Soomin Cho, Jaewon Roh, Hayoon Jeong, Yoon Jeong Park, Kun Na · 2026 · Chemical Engineering Journal
  31. From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
    Wei-Xiang Wang, Chen‐Chi Wang, Wei-Cherng Hsu, Yi-Jie Peng · 2026 · Journal of Ophthalmology
  32. The role of adjunctive aqueous suppressants for anti-vascular endothelial growth factor therapy: A systematic review
    Kareem Sadek, Philip Yu, Salem Abu Al-Burak et al. · 2026 · Survey of Ophthalmology
  33. A human amelotin transgenic mouse model with calcified deposits similar to those in dry age-related macular degeneration
    Dinusha Rajapakse, Jianguo Fan, Dannika Daily, Lijin Dong, Katherine M. Peterson, Robert N. Fariss, Graeme J. Wistow · 2026 · Experimental Eye Research
  34. Switching to faricimab in cases of limited response to aflibercept in patients with neovascular age-related macular degeneration – report of two clinical cases
    Mateusz Raniewicz, Monika Grudzień, Anna Święch · 2026 · Ophthalmology
  35. Long-Term Predictive Value of Macular Thickness Fluctuations in Response to Anti-VEGF Treatment for Age-Related Macular Degeneration
    Alison H. Zhao, Taseen A. Alam, Nikhil Das, Christopher M. Maatouk, Rishi P. Singh, Katherine E. Talcott · 2026 · Journal of VitreoRetinal Diseases
  36. Serum microRNA-34a as a circulating biomarker for age-related macular degeneration and short-term anti-VEGF response in neovascular AMD
    Meng Kong, Rong Jin, Tongjie Cheng · 2026 · BMC Ophthalmology
  37. 2-year real-world clinical outcomes on the use of Faricimab in neovascular age-related macular degeneration
    Corinne Fulcher, Faruque D. Ghanchi · 2026 · Eye Open
  38. Association of interleukin-6 pathway inhibition with risk of age-related macular degeneration: A propensity-matched cohort study
    Mirataollah Salabati, Leila Mabudian, Sharanya Deshmukh · 2026 · European Journal of Ophthalmology
  39. Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication
    Daniele Veritti, Valentina Sarao, Marco Lupidi et al. · 2026 · Graefe s Archive for Clinical and Experimental Ophthalmology
  40. Faricimab for High-Need Aflibercept 2 mg–Treated Neovascular Age-Related Macular Degeneration: A Randomized Comparator-Controlled Trial
    Monja Michelitsch, Regina Riedl, Sanja Strini · 2026 · Ophthalmology Retina
  41. Adjuvant mecobalamin for anti-VEGF therapy in retinal vein occlusion: protocol of a single-centre, randomised, double-blinded controlled trial
    Ke-Yu Liu, Qing-Yue Luo, LI Zhou-yu, Ren-Yue Xiao, Chen Zeng, Xuedong Zhang, S X Liu, Wen-Li Deng, Yan-lai Zhang · 2026 · BMJ Open
  42. Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study
    Dun Jack Fu, Eleonora Riotto, Luke Nicholson, Sandro Fasolo, Omer Trivizki, Kimberly Spooner, Sobha Sivaprasad, Livia Faes · 2026 · Ophthalmology and Therapy
  43. Bridging policy gaps in clinical trial volunteering: public and healthcare professional perspectives in England
    Khawaja Muhammad Ammar Ali Javed, Gibran Farook Butt, Gurpreet Bansal, Maryam Noeman, Philip I. Murray, Saaeha Rauz · 2026 · BMJ Open Ophthalmology
  44. Real-world outcomes after switching to faricimab in treatment-resistant neovascular AMD: Short-term response and 12-month follow-up
    Victoria Marechal, Francesca Amoroso, Sorana PACURARIU · 2026 · European Journal of Ophthalmology
  45. The APOE ε2 allele is associated with risk of neovascular age-related macular degeneration in a Russian cohort
    Oyuna S. Kozhevnikova, Ida F. Nikulich, Anna S. Derbeneva · 2026 · Vavilov Journal of Genetics and Breeding
  46. The oxidative and carbonyl stress axis in anti-vascular endothelial growth factor-refractory neovascular age-related macular degeneration: Implications for therapeutic repurposing
    Diana Carolina Castro-Fernández, Antonio Cañizo-Outeiriño, Antón Leandro Martínez, Andrea Cuartero‐Martínez, Lorena Jazmín Rodríguez Martinez, Miguel González‐Barcia, María Isabel Fernández-Rodríguez, María José Rodríguez‐Cid, Maximino José Abraldes, Pablo Almuiña-Varela et al. · 2026 · European Journal of Medicinal Chemistry
  47. Ranibizumab port delivery system for neovascular age-related macular degeneration: Current evidence and surgical considerations
    Alberto Quarta, Sobha Sivaprasad, Tien Y Wong · 2026 · Graefe s Archive for Clinical and Experimental Ophthalmology
  48. Intravitreal injection switch to brolucizumab in refractory and chronic neovascular age-related macular degeneration: a real-world study in Brazil
    Gabriel Pinheiro Santos, Raphael Caetano Rosa Abreu, Matheus Madeiro, Camila Vieira Oliveira Carvalho Ventura, Fabiana Karla Aquino da Costa · 2026 · Revista Brasileira de Oftalmologia
  49. Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study
    Jules Fricker, Lucas Séjournet, Jules Prange, Julien Andre, Remy Calvet, Valentin Rougane, Ségolène Gouze, Maxime Oudard, Ambre Ancel, Alexis Kodjikian et al. · 2026 · Ophthalmology and Therapy